GSK plc reports

Company location
London
GSK plc has filed 6,846 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 776-800 of 1,000 matching filings.

Per page
25
Current page
32
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Dec 2023
Reporting date
01 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

BLOCK LISTING APPLICATION

Filing date
30 Nov 2023
Reporting date
30 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

HOLDING(S) IN COMPANY

Filing date
29 Nov 2023
Reporting date
29 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS

Filing date
27 Nov 2023
Reporting date
27 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
21 Nov 2023
Reporting date
21 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

BLOCK LISTING INTERIM REVIEW

Filing date
15 Nov 2023
Reporting date
15 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Nov 2023
Reporting date
13 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB

Filing date
13 Nov 2023
Reporting date
13 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Nov 2023
Reporting date
01 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

3RD QUARTER RESULTS

Filing date
01 Nov 2023
Reporting date
01 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT

Filing date
30 Oct 2023
Reporting date
30 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA

Filing date
26 Oct 2023
Reporting date
26 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
25 Oct 2023
Reporting date
25 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NEW DATA FOR AREXVY, GSK'S RSV VACCINE

Filing date
25 Oct 2023
Reporting date
25 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
20 Oct 2023
Reporting date
20 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
18 Oct 2023
Reporting date
18 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
17 Oct 2023
Reporting date
17 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION

Filing date
16 Oct 2023
Reporting date
16 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Oct 2023
Reporting date
13 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
12 Oct 2023
Reporting date
12 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

ZANTAC (RANITIDINE) LITIGATION

Filing date
11 Oct 2023
Reporting date
11 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A

AMENDMENT TO FORM SC 13D

Filing date
10 Oct 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP

Filing date
10 Oct 2023
Reporting date
10 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

CURRENT REPORT

Filing date
06 Oct 2023
Reporting date
06 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK COMPLETES SALE OF SHARES IN HALEON PLC

Filing date
06 Oct 2023
Reporting date
06 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .